Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

Pavord, 1999, Non-eosinophilic corticosteroid unresponsive asthma, Lancet, 353, 2213, 10.1016/S0140-6736(99)01813-9 Berry, 2007, Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma, Thorax, 62, 1043, 10.1136/thx.2006.073429 Busse, 2000, Pathophysiology of severe asthma, J Allergy Clin Immunol, 106, 1033, 10.1067/mai.2000.111307 Brightling, 2008, Targeting TNF-alpha: a novel therapeutic approach for asthma, J Allergy Clin Immunol, 121, 5, 10.1016/j.jaci.2007.10.028 Holgate, 2006, Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities, J Allergy Clin Immunol, 117, 496, 10.1016/j.jaci.2006.01.039 Uddin, 2010, Prosurvival activity for airway neutrophils in severe asthma, Thorax, 65, 684, 10.1136/thx.2009.120741 Nair, 2015, Therapeutic implications of ‘neutrophilic asthma’, Curr Opin Pulm Med, 21, 33, 10.1097/MCP.0000000000000120 Hauber, 2003, Effect of HFA-flunisolide on peripheral lung inflammation in asthma, J Allergy Clin Immunol, 112, 58, 10.1067/mai.2003.1612 MacDowell, 2007, Neutrophils in asthma, Curr Allergy Asthma Rep, 7, 464, 10.1007/s11882-007-0071-6 Chapman, 2009, CXCR2 antagonists for the treatment of pulmonary disease, Pharmacol Ther, 121, 55, 10.1016/j.pharmthera.2008.10.005 Gernez, 2010, Neutrophils in chronic inflammatory airway diseases: can we target them and how?, Eur Respir J, 35, 467, 10.1183/09031936.00186109 Chapman, 2007, A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation, J Pharmacol Exp Ther, 322, 486, 10.1124/jpet.106.119040 Day, 2012, Regulation of neutrophil trafficking from the bone marrow, Cell Mol Life Sci, 69, 1415, 10.1007/s00018-011-0870-8 Rennard, 2015, CXCR2 antagonist MK-7123–a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 191, 1001, 10.1164/rccm.201405-0992OC Nair, 2012, Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial, Clin Exp Allergy, 42, 1097, 10.1111/j.1365-2222.2012.04014.x Moss, 2013, Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis, J Cyst Fibros, 12, 241, 10.1016/j.jcf.2012.08.016 De Soyza, 2015, A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis, Eur Respir J, 46, 1021, 10.1183/13993003.00148-2015 Kirsten, 2015, The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD, Pulm Pharmacol Ther, 31, 36, 10.1016/j.pupt.2015.02.001 Jurcevic, 2015, The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions, Br J Clin Pharmacol, 80, 1324, 10.1111/bcp.12724 Nicholls, 2015, Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist, J Pharmacol Exp Ther, 353, 340, 10.1124/jpet.114.221358 Fahy, 1995, Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation, J Allergy Clin Immunol, 95, 843, 10.1016/S0091-6749(95)70128-1 Turner, 1995, Exacerbations of asthma without sputum eosinophilia, Thorax, 50, 1057, 10.1136/thx.50.10.1057 Hanania, 2011, Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial, Ann Intern Med, 154, 573, 10.7326/0003-4819-154-9-201105030-00002 Humbert, 2005, Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE, Allergy, 60, 309, 10.1111/j.1398-9995.2004.00772.x Vignola, 2004, Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR, Allergy, 59, 709, 10.1111/j.1398-9995.2004.00550.x Wenzel, 2009, A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma, Am J Respir Crit Care Med, 179, 549, 10.1164/rccm.200809-1512OC McCullagh, 1989 Uddin, 2013, EGF-induced bronchial epithelial cells drive neutrophil chemotactic and anti-apoptotic activity in asthma, PloS One, 8, e72502, 10.1371/journal.pone.0072502 Kupczyk, 2014, Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma, Allergy, 69, 1198, 10.1111/all.12445 Zhang, 2014, Full blood count parameters for the detection of asthma inflammatory phenotypes, Clin Exp Allergy, 44, 1137, 10.1111/cea.12345